Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise.
Arcutis Biotherapeutics(US:ARQT) Investorsยท2025-10-28 15:34BREAKING: Stocks Rumble Higher As PayPal, UnitedHealth RallyArcutis Biotherapeutics (ARQT) smashed third-quarter expectations Tuesday and reported its first-ever positive net income, leading Arcutis stock to skyrocket.In late morning trades, Arcutis stock surged more than 24% to 24.49. Shares topped a profit-taking zone after, last month, breaking out of a cup base.The company makes Zoryve, a cream that treats skin conditions like psoriasis and eczema. During the third quarter, Zoryve generated $99.2 millio ...